European Economic Area

DGAP-News: CPI PROPERTY GROUP: AMENDED CONVENING NOTICE OF THE COMPANY'S EXTRAORDINARY GENERAL MEETING TO BE HELD ON 16 DECEMBER 2021

Friday, November 26, 2021 - 5:03pm

The convening notice for the Meeting was published on 13 November 2021 in the Luxembourg newspaper Tageblatt and on 15 November 2021 in the Luxembourg official gazette (Recueil Electronique des Socits et Associations).

Key Points: 
  • The convening notice for the Meeting was published on 13 November 2021 in the Luxembourg newspaper Tageblatt and on 15 November 2021 in the Luxembourg official gazette (Recueil Electronique des Socits et Associations).
  • Following the request of the Requesting Shareholder, the agenda of the Meeting is revised as follows (the "Revised Agenda"):
    1.
  • The Record Date Confirmation must be in writing and indicate that a shareholder holds the Company shares and wishes to participate in the Meeting.
  • With respect to item 3 of the Revised Agenda, the Meeting shall validly deliberate regardless of the corporate capital present or represented.

Société du Grand Paris : final terms serie 17 Issue of EUR 1,250,000,000 1.000 per cent. Notes due 26 November 2051

Thursday, November 25, 2021 - 2:04pm

Socit du Grand Paris : final terms serie 17 Issue of EUR 1,250,000,000 1.000 per cent.

Key Points: 
  • Socit du Grand Paris : final terms serie 17 Issue of EUR 1,250,000,000 1.000 per cent.
  • Notes due 26 November 2051
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • This document constitutes the Final Terms of the Notes described herein for the purposes of the Prospectus Regulation and must be read in conjunction with such Base Prospectus.
  • The Final Terms and the Base Prospectus will be available on the Issuer's website ( https://www.societedugrandparis.fr/publications-financieres-1870 ) and on the AMF's website ( www.amf-france.org ).

Société du Grand Paris : Final terms - Issue of EUR 1,750,000,000 0.300 per cent. Notes due 25 November 2031

Thursday, November 25, 2021 - 2:04pm

Socit du Grand Paris : Final terms - Issue of EUR 1,750,000,000 0.300 per cent.

Key Points: 
  • Socit du Grand Paris : Final terms - Issue of EUR 1,750,000,000 0.300 per cent.
  • Notes due 25 November 2031
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • This document constitutes the Final Terms of the Notes described herein for the purposes of the Prospectus Regulation and must be read in conjunction with such Base Prospectus.
  • The Final Terms and the Base Prospectus will be available on the Issuer's website ( https://www.societedugrandparis.fr/publications-financieres-1870 ) and on the AMF's website ( www.amf-france.org ).

DGAP-News: The Social Chain AG: Social Chain AG successfully completes capital increase: Kick-off for operational integration of DS Group

Wednesday, November 24, 2021 - 1:07pm

The Social Chain AG: Social Chain AG successfully completes capital increase: Kick-off for operational integration of DS Group

Key Points: 
  • The Social Chain AG: Social Chain AG successfully completes capital increase: Kick-off for operational integration of DS Group
    The issuer is solely responsible for the content of this announcement.
  • Social Chain AG successfully completes capital increase:
    Placement of 1,145,324 new shares: gross issue proceeds of EUR 53 million
    Berlin, 24 November 2021.
  • Wanja S. Oberhof, CEO of Social Chain AG: "The capital increase is the kick-off for the operative cooperation with DS Group.
  • About The Social Chain AG: Social Commerce on a global scale
    Social Chain AG is reshaping the world of brands and commerce with Social Commerce.

DGAP-News: Photon Energy Group Increases 6.50% Green EUR Bond 2021/2027 to 55 Million Euros

Wednesday, November 24, 2021 - 9:03am

An investment decision regarding the publicly offered securities of Photon Energy N.V. should only be made on the basis of the securities prospectus.

Key Points: 
  • An investment decision regarding the publicly offered securities of Photon Energy N.V. should only be made on the basis of the securities prospectus.
  • The securities prospectus was published promptly upon approval by the CSSF, and is available at no charge on www.photonenergy.com.
  • There will be no public offering of securities of Photon Energy N.V.
  • Photon Energy N.V. assumes no responsibility to update any forward-looking statements contained in this release.

DGAP-News: Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid(R) Products Covering 30 Countries in Europe

Wednesday, November 24, 2021 - 8:01am

New York, NY, and Tel Aviv, ISRAEL - via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its joint venture partner NLC Pharma, Ltd., today announced that it has entered into an exclusive European licensing & distribution agreement with T-Cell Protect Hellas S.A. (T-Cell Protect or T-Cell) for a product based on its Tollovid(R) and Tollovid Daily(TM) 3CL protease inhibitor and immune support dietary supplements. The product will be marketed under the T-Cell Protect brand throughout 30 countries in Europe with the agreement calling for a minimum of 500,000 bottles in sales over 18 months. T-Cell has placed an initial purchase order for 50,000 bottles of the Tollovid Daily product that is expected to meet the demand of an initial rollout to a subset of the 11,000 stores located throughout Greece. More information about the product can be found at www.tcellprotect.com. Under the terms of the agreement, T-Cell Protect will purchase finished product at wholesale from Todos until such time as T-Cell Protect establishes manufacturing capabilities at a facility it currently operates in Greece to support the European market. At such time, Todos will then receive double-digit royalties on the sales of the licensed product manufactured by T-Cell Protect. The Company anticipates revenue to be generated from this agreement beginning in the current quarter.

Key Points: 
  • Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid(R) Products Covering 30 Countries in Europe
    The issuer is solely responsible for the content of this announcement.
  • The product will be marketed under the T-Cell Protect brand throughout 30 countries in Europe with the agreement calling for a minimum of 500,000 bottles in sales over 18 months.
  • At such time, Todos will then receive double-digit royalties on the sales of the licensed product manufactured by T-Cell Protect.
  • "We believe this distribution agreement & related investment validates our commercial approach for our Tollovid and Tollovid Daily products," said Gerald E. Commissiong, President & CEO of Todos Medical.

Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid® Products Covering 30 Countries in Europe

Wednesday, November 24, 2021 - 7:00am

The product will be marketed under the T-Cell Protect brand throughout 30 countries in Europe with the agreement calling for a minimum of 500,000 bottles in sales over 18 months.

Key Points: 
  • The product will be marketed under the T-Cell Protect brand throughout 30 countries in Europe with the agreement calling for a minimum of 500,000 bottles in sales over 18 months.
  • At such time, Todos will then receive double-digit royalties on the sales of the licensed product manufactured by T-Cell Protect.
  • The potential for Tollovid and Tollovid Daily in Europe is quite significant and we are excited to bring them to market.
  • We believe this distribution agreement & related investment validates our commercial approach for our Tollovid and Tollovid Daily products, said Gerald E. Commissiong, President & CEO of Todos Medical.

DGAP-News: Delivery Hero SE: Placement price for new shares issued in connection with existing stock option program and sold for option holders has been set

Monday, November 22, 2021 - 9:06pm

0,24 % of Delivery Hero's registered share capital, will be issued to beneficiaries of the stock option program who have exercised their stock options.

Key Points: 
  • 0,24 % of Delivery Hero's registered share capital, will be issued to beneficiaries of the stock option program who have exercised their stock options.
  • Delivery Hero's registered share capital will be increased by an amount of EUR 591,854.00 from EUR 250,303,504.00 to EUR 250,895,358.00.
  • The placement price for the New Shares was set at EUR 122.50.
  • In connection with the transaction described above (the 'Placement'), UniCredit Bank AG is acting exclusively for Delivery Hero SE.

DGAP-News: Delivery Hero SE: Issuance of new shares in connection with existing stock option program and sale of shares for option holders by way of accelerated bookbuilding

Monday, November 22, 2021 - 7:22pm

0,24 % of Delivery Hero's registered share capital, will be issued to beneficiaries of the stock option program who have exercised their stock options.

Key Points: 
  • 0,24 % of Delivery Hero's registered share capital, will be issued to beneficiaries of the stock option program who have exercised their stock options.
  • The New Shares, like all other outstanding shares of Delivery Hero, will carry full dividend rights as of 1 January 2021 and be admitted to trading and included in the existing quotation for Delivery Hero's shares on the Frankfurt Stock Exchange.
  • Delivery of the New Shares to institutional investors is expected for 26 November 2021.
  • In connection with the transaction described above (the 'Placement'), UniCredit Bank AG is acting exclusively for Delivery Hero SE.

DGAP-News: Mynaric announces closing of public offering in the United States

Monday, November 22, 2021 - 7:17pm

Gilching, November 21, 2021 - Mynaric AG (Nasdaq: MYNA; Frankfurt Stock Exchange: M0Y) announced today the closing of its public offering on November 16, 2021 in the United States of 4,000,000 American Depositary Shares ("ADSs").

Key Points: 
  • Gilching, November 21, 2021 - Mynaric AG (Nasdaq: MYNA; Frankfurt Stock Exchange: M0Y) announced today the closing of its public offering on November 16, 2021 in the United States of 4,000,000 American Depositary Shares ("ADSs").
  • All ADSs sold in the public offering were offered by Mynaric at a public offering price of USD 16.50 per ADS.
  • The Option closed on November 18, 2021 and was subject to customary closing conditions.
  • Copies of the final prospectus relating to the offering may be obtained for free by visiting EDGAR on the SEC's website at www.sec.gov.